Approved drugSleep and stress neuropeptide

DSIP

Delta sleep-inducing peptide, emideltide

Common dose: 100–300 mcg before bed
Cycle: 2 weeks on, 2 off
Vial sizes: 5, 10 mg
Typical draw: 10 units5 mg with 2 mL, 250 mcg

A nine-amino-acid neuropeptide first isolated in the 1970s from the blood of sleeping rabbits.

Evidence. Registered in Russia as Deltaran (intranasal) for stress states and, as add-on therapy, alcohol withdrawal. Older insomnia trials found weak effects.

Status

Approval: Approved in Russia as Deltaran, an intranasal product for stress states and alcohol withdrawal; not approved in the US.
US compounding: Nomination withdrawn, so emideltide (DSIP) is no longer in FDA Category 2 (April 2026). On July 24, 2026 FDA’s advisory committee voted 7 to 6, 1 abstaining, against adding it to the 503A bulks list.
Sport (WADA 2026): Not banned in sportNot named on the 2026 list. It is registered in Russia (Deltaran), so S0 (non-approved substances) does not apply.

Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026.

Protocol

Label

Deltaran, Russia

300 mcg intranasal, 1–3× daily for 5–10 days.

Trial

1980s–90s insomnia studies

IV: about 25 nmol/kg (roughly 21 mcg/kg) per infusion.

Community

100–300 mcg by injection, 1–3 hours before bed.

Frequency: Once nightly
Route: Intranasal (label); injection (community)
Timing: Evening, 1–3 hours before bed.
Cycle: Label: 5–10 days. Community: 5–7 nights up to about 4 weeks, then a break.
2 weeks on, 2 off, shown over 26 weeks

Common protocols

The ways DSIP is most often run, each tagged with where it comes from.

Label course

Label

Dose: 300 mcg (one ampule) intranasal
How often: 1–3× daily
How long: 5–10 days

Russian Deltaran, as add-on therapy for stress states and alcohol withdrawal.

IV insomnia trial

Trial

Dose: 25 nmol/kg (about 21 mcg/kg) IV
How often: Once daily, in the afternoon
How long: 3 days

16 people with chronic insomnia (Bes 1992). The effect was weak.

Community injection

Community

Dose: 100–300 mcg
How often: Once nightly, 1–3 hours before bed
How long: 5–7 nights up to about 4 weeks, then a break

Under the skin. No human data for injection.

Draw 4–12 units5 mg + 2 mL

Dosing by body weight

Trial

25 nmol/kg. IV, 3 afternoon infusions in 16 insomnia patients (Bes 1992); about 21 mcg/kg. The effect was weak.

Taking it

Where it goes

Label: dissolve one 0.3 mg ampule in 0.5 mL of water just before use and drop into both nostrils; clear a blocked nose first. Community injections go under the skin.

If you miss a dose

The Deltaran label has no missed-dose rule. Skip it and resume on schedule; don’t double up.

What to expect

Nights 3–5 (IV trial)
Slightly better sleep efficiency and faster sleep onset than placebo, but no change in how well people felt they slept.
Trial
After a short course
Trial authors concluded short-term DSIP is unlikely to be of major benefit for chronic insomnia.
Trial
5–10 day label course
The label gives no timeline for effects in stress states or alcohol withdrawal.
Label

Side effects and what to do

Nasal irritation (Deltaran label; frequency not given)

Clear the nose before dosing; stop if it persists.

Allergic reactions (Deltaran label; frequency not given)

Stop and get help for rash, swelling or trouble breathing.

Headache, nausea or dizziness (reported in older trials)

Usually mild; stop if they persist.

Stop and get medical help

Fainting, a very slow pulse, chest pain, or allergy signs such as rash, swelling or trouble breathing.

Tracking and pairing

Worth tracking

Pulse, if it tends to run slow (label caution)
Sleep quality, to judge whether it helps

Often paired with

Usually run on its own.

Human studies

5 key published human studies, with how many people took part. Animal studies aren’t listed here.

1984107 people

In alcohol (47) and opiate (60) withdrawal, symptoms cleared or improved markedly in 87% and 97% of evaluable patients; there was no control group.

Design
Open uncontrolled study
Dose
IV injections

Dick et al., Eur Neurol 1984, PMID 6548969
200924 people

Rather than deepening anesthesia, DSIP raised heart rate and lightened anesthesia depth (higher BIS) at 25 nmol/kg.

Design
Randomized controlled trial, add-on to anesthesia
Dose
25 to 100 nmol/kg IV
Length
Single doses around surgery

Pomfrett et al., Eur J Anaesthesiol 2009, PMID 19142086
199216 people

In chronic insomnia, sleep efficiency and sleep onset improved slightly vs placebo, but effects were weak and subjective sleep did not change.

Design
Double-blind placebo-controlled trial
Dose
25 nmol/kg IV
Length
3 afternoons

Bes et al., Neuropsychobiology 1992, PMID 1299794
198714 people

In severe chronic insomnia, night sleep and daytime alertness improved substantially, and the effect held for one placebo night afterward.

Design
Double-blind placebo-controlled study
Length
7 nights

Schneider-Helmert, Eur Neurol 1987, PMID 3622582
1987

In chronic insomnia, total sleep time rose, but the gap vs placebo already existed at baseline; judged of little clinical value.

Design
Double-blind crossover trial
Dose
25 nmol/kg IV
Length
4 nights

Monti et al., Int J Clin Pharmacol Res 1987, PMID 3583493

Mixing your vial

Vial	Water	Common dose	Draw	Strength	Action
5 mg	2 mL	250 mcg	10 units (0.10 mL)	2.5 mg/mL
10 mg	2 mL	250 mcg	5 units (0.05 mL)	5 mg/mL

Dose chart

Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.

Dose	Water added
Dose	1 mL	2 mL	3 mL
100 mcg
150 mcg
200 mcg
250 mcg
300 mcg

U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.

Datasheet

Half-life: No reliable value has been published.
Type: Peptide, 9 amino acids
Molecular weight: 848.8 g/mol
Formula: C₃₅H₄₈N₁₀O₁₅
Sequence: WAGGDASGE
Storage before use: Deltaran label: 2–15 °C, protected from light (licensed 0.3 mg vial, 3-year shelf life).
After mixing or opening: Deltaran label: use at once, don’t store. Multi-dose research vials are commonly kept in the fridge and used within about 4 weeks.

Molecule: PubChem CID 68816
Storage: Label Deltaran instructions (RLS, Russian)

Cautions

Label: not for pregnancy, breastfeeding, under 18, or a very slow heart rate (severe bradycardia).
Headache, nausea and dizziness were reported in trials.
No human data for injection.

Questions

What is DSIP?

A nine-amino-acid neuropeptide first isolated in the 1970s from the blood of sleeping rabbits.

Is DSIP FDA-approved?

Approved in Russia as Deltaran, an intranasal product for stress states and alcohol withdrawal; not approved in the US. Nomination withdrawn, so emideltide (DSIP) is no longer in FDA Category 2 (April 2026). On July 24, 2026 FDA’s advisory committee voted 7 to 6, 1 abstaining, against adding it to the 503A bulks list.

What is the usual DSIP dose?

From the label (Deltaran, Russia): 300 mcg intranasal, 1–3× daily for 5–10 days. From human studies (1980s–90s insomnia studies): IV: about 25 nmol/kg (roughly 21 mcg/kg) per infusion. These are the amounts sources reference, not recommendations.

How much water do I mix DSIP with?

There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 5 mg vial, the strength is 2.5 mg/mL, so 250 mcg is 10 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.

How should DSIP be stored?

Before mixing: Deltaran label: 2–15 °C, protected from light (licensed 0.3 mg vial, 3-year shelf life). Deltaran label: use at once, don’t store. Multi-dose research vials are commonly kept in the fridge and used within about 4 weeks.

Is DSIP banned in sport?

No. Not named on the 2026 list. It is registered in Russia (Deltaran), so S0 (non-approved substances) does not apply.

Has DSIP been studied in people?

Yes. The human studies section lists 5 published studies. Among them, from 1984: In alcohol (47) and opiate (60) withdrawal, symptoms cleared or improved markedly in 87% and 97% of evaluable patients; there was no control group.

Sources

Deltaran instructions (RLS, Russian)
Bes et al., DSIP in chronic insomnia (Neuropsychobiology 1992)
FDA advisory committee backs 6 peptides for compounding (AJMC, July 2026)

For the protocol details

Bes et al. 1992, DSIP in chronic insomnia, double-blind study (Neuropsychobiology abstract)

Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.

By Vial Guide editorsLast reviewed October 5, 2026

How we review